Does platelet aggregation differ among chronic myeloid leukemia-chronic phase (CML-CP) patients on tyrosine kinase inhibitors (TKIs)? A tertiary center experience

كلية الطب

جامعة أسيوط

Does platelet aggregation differ among chronic myeloid leukemia-chronic phase (CML-CP) patients on tyrosine kinase inhibitors (TKIs)? A tertiary center experience

مؤلف البحث
Sawsan M Moeen, Ola A Afifi, Ahmad F Thabet, Medhat A Saleh, Mohamed A Morad
تاريخ البحث
قسم البحث
قسم الأمراض الباطنة
مجلة البحث
The Egyptian Journal of Haematology
المشارك في البحث
Sawsan Mohamed Moeen Ibrahim
الناشر
Medknow
عدد البحث
Volume 48 Issue 2
موقع البحث
https://scholar.google.com/scholar?oi=bibs&cluster=14321767449787589482&btnI=1&hl=en
سنة البحث
2023
صفحات البحث
185-190
ملخص البحث

Tyrosine kinase inhibitors (TKIs) have improved the prognosis of chronic myeloid leukemia (CML) by inhibiting the BCR-ABL kinase. There are concerns regarding the effect of TKI on hemostasis by inhibiting platelet aggregation; the possible reason for this is yet unclear.

Objectives

To study platelet aggregation response to different agonists [(adenosine diphosphate (ADP), collagen, and arachidonic acid (AA)] using platelet aggregometry in 75 CML-chronic phase (CML-CP) patients on TKI therapy, in complete hematologic response (CHR).